Latest news for Piraeus Finl Hldgs (OTC:BPIRF) Stock

Piraeus Financial Holdings SA is a universal banking group operating in Greece but with a presence in southeastern Europe and the eastern Mediterranean. Its banking unit specializes in small to midsize enterprise banking, agricultural banking, consumer and mortgage credit, green banking, investment banking, as well as leasing and factoring. The bank has an extensive distribution network, both traditional and alternative, the majority of notably its e-banking platform Winbank. A majority of the bank's net revenue is net interest income, overwhelmingly derived from loans and advances to customers.

PIRAEUS FINL HLDGS SA by PIRAEUS FINL HLDGS S A

Piraeus Financial Holdings SA

WIIM

Eagle Materials shares are trading higher after the company reported better-than-expected Q1 EPS results.

Stephens &amp; Co. analyst Terry McEvoy maintains Byline Bancorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BY#NYSE">BY</a>) with a Equal-Weight and raises the price target from $27 to $29.

News

Price Target

Analyst Ratings

Stephens & Co. Maintains Equal-Weight on Byline Bancorp, Raises Price Target to $29

LGIH

LGI Homes shares are trading higher after the company reported better-than-expected Q2 EPS results.

Trading Ideas

VBIV

VBI Vaccines Shares Resume Trade

B of A Securities analyst Craig Siegenthaler upgrades LPL Finl Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPLA#NASDAQ">LPLA</a>) from Neutral to Buy and announces $268 price target.

Upgrades

LPLA

B of A Securities Upgrades LPL Finl Hldgs to Buy, Announces $268 Price Target

JBLU

JetBlue Airways CEO Says Our Revenue Growth Has Not Been Enough To Outpace Our Cost Challenges; Pratt & Whitney Engine Related Aircraft Groundings Are Significantly Impeding Our Growth Rate, Pressuring Our Profitability

Phillips 66 shares are trading higher after the company reported better-than-expected Q2 financial results.

As of July 30, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the <a href="https://www.benzinga.com/topic/rsi">RSI is above 70</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>. 
Here's the latest list of major overbought players in this sector.
<h3 class="wp-block-heading">Verona Pharma PLC &#8211; ADR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRNA#NASDAQ">VRNA</a>)</h3>
<ul>
<li>Verona Pharma will report its financial results for the second quarter on Thursday, Aug. 8. The company's stock gained around 46% over the past month and has a <a href="https://www.benzinga.com/quote/VRNA">52-week high of</a> $23.72.</li>
<li>RSI Value: 71.29&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>VRNA Price Action: Shares of Verona Pharma fell 0.5% to close at $22.61 on Monday.</li>
</ul>
<h3 class="wp-block-heading">Catalyst Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPRX#NASDAQ">CPRX</a>)</h3>
<ul>
<li>On July 24, Catalyst Pharmaceuticals entered into an exclusive license, supply and commercialization agreement with Kye Pharmaceuticals for AGAMREE&#xAE; in Canada. &#8220;We are pleased to enter into this agreement with Kye Pharmaceuticals for AGAMREE, marking a pivotal milestone in our strategic initiative to expand the product&#8217;s footprint in North America. This collaboration leverages our combined expertise, fortifies our alliance by licensing our second therapeutic rare disease product for Canada, and demonstrates our sustained commitment to patient care,&#8221; stated Richard J. Daly, CEO and President of Catalyst. The company's stock gained around 11% over the past month and <a href="https://www.benzinga.com/quote/CPRX">has a 52-week high</a> of $17.99.</li>
<li>RSI Value: 70.99</li>
<li>CPRX Price Action: Shares of Catalyst Pharmaceuticals fell 0.6% to close at $17.48 on Monday.</li>
</ul>
<h3 class="wp-block-heading">Viridian Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRDN#NASDAQ">VRDN</a>)</h3>
<ul>
<li>On July 29, Wedbush maintained an Outperform rating on the stock and reiterated its price target of $42. The company's stock gained around 31% over the past month and has a <a href="https://www.benzinga.com/quote/VRDN">52-week high</a> of $24.18.</li>
<li>RSI Value: 73.86</li>
<li>VRDN Price Action: Shares of Viridian Therapeutics gained 3.8% to close at $17.29 on Monday.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/24/07/40009447/roblox-morgan-stanley-and-2-other-stocks-insiders-are-selling">Roblox, Morgan Stanley And 2 Other Stocks Insiders Are Selling</a></li>
</ul>

Short Ideas

Markets

CPRX

VRDN

VRNA

Top 3 Health Care Stocks You May Want To Dump This Quarter

Starbucks Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>) will release its third quarter financial results, after the <a href="https://www.benzinga.com/quote/SBUX/earnings">closing bell on Tuesday, July 30.</a>
Analysts expect the Seattle, Washington-based company to report quarterly earnings at 93 cents per share, down from $1 per share in the year-ago period. Starbucks expects to post revenue of $9.24 billion, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
According to a recent WSJ report, Elliott Investment Management has taken a significant stake in the coffee giant.
Starbucks shares gained 1.5% to close at $75.14 on Monday.
Benzinga readers can access the latest analyst ratings on the<a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie"> Analyst Stock Ratings </a>page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/SBUX/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/592423ce290fa700011180e0/jon-tower">Citigroup analyst Jon Tower</a> maintained a Neutral rating and cut the price target from $85 to $80 on July 22. This analyst has an accuracy rate of 71%.</li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5df37c17bffdfc0001d738fc/brian-mullan">Deutsche Bank analyst Brian Mullan</a> maintained a Hold rating and slashed the price target from $89 to $85 on July 16. This analyst has an accuracy rate of 75%.</li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/587e33185064ed0001730304/john-ivankoe">JP Morgan analyst John Ivankoe</a> maintained an Overweight rating and cut the price target from $92 to $90 on July 10. This analyst has an accuracy rate of 72%.</li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5df37c17bffdfc0001d738fc/brian-mullan">Piper Sandler analyst Brian Mullan</a> maintained a Neutral rating and lowered the price target from $88 to $85 on May 6. This analyst has an accuracy rate of 75%.</li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/653645581c7d4600012cd535/meredith-jensen">HSBC analyst Meredith Jensen</a> maintained a Hold rating and cut the price target from $107 to $84 on May 3. This analyst has an accuracy rate of 71%.</li>
</ul>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/07/40011827/more-than-4m-bet-on-appian-check-out-these-3-stocks-insiders-are-buying">More Than $4M Bet On Appian? Check Out These 3 Stocks Insiders Are Buying</a></li>
</ul>

Earnings

SBUX

Starbucks Likely To Report Lower Q3 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Biotech

General

Merck Exec Says Targeting Next Year's RSV Season In U.S. For RSV Antibody

U.S. stocks traded mostly higher this morning, with the Dow Jones index gaining around 200 points on Tuesday.
Following the market opening Tuesday, the Dow traded up 0.50% to 40,742.44 while the NASDAQ slipped 0.01% to 17,370.07. The S&amp;P 500 also rose, gaining, 0.22% to 5,475.80.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/07/40036066/top-3-financials-stocks-which-could-rescue-your-portfolio-for-july">Top 3 Financials Stocks Which Could Rescue Your Portfolio For July</a>
Leading and Lagging Sectors Financials shares jumped by 1.3% on Tuesday.
In trading on Tuesday, consumer staples shares fell by 1%.
Top Headline
Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) reported better-than-expected second-quarter financial results.
Pfizer reported second-quarter adjusted EPS of 60 cents, down 11% year over year, beating the consensus of 46 cents. The U.S. drugmaker reported sales of $13.28 billion, up 2% year-over-year (up 3% operationally), beating the consensus of $13.02 billion.
Pfizer updated its 2024 revenue forecast to $59.5 billion—$62.5 billion, compared to prior guidance of $58.5 billion—$61.5 billion and consensus of $60.7 billion. Pfizer expects 2024 adjusted EPS of $2.45-$2.65 compared to prior guidance of $2.15-$2.35 and consensus of $2.37.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Imunon, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMNN#NASDAQ">IMNN</a>) shares shot up 158% to $3.0500 after the company announced topline results from its Phase 2 OVATION 2 study with IMNN-001. The results showed an 11.1-month improvement in median overall survival compared to standard-of-care alone in the intent-to-treat population.</li>
<li>Shares of Agape ATP Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATPC#NASDAQ">ATPC</a>) got a boost, surging 100% to $0.1766. AGAPE ATP strengthened wellness division via innovative incubation with emerging local SMEs.</li>
<li>Processa Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCSA#NASDAQ">PCSA</a>) shares were also up, gaining 44% to $2.44 after the company announced FDA clearance of its IND application for a Phase 2 clinical trial of NGC-Cap in breast cancer.</li>
</ul>
Equities Trading DOWN
<ul>
<li>QXO, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QXO#NASDAQ">QXO</a>) shares dropped 79% to $12.37. This sudden decline was triggered by the registration of two private placements with the U.S. Securities and Exchange Commission, which unlocked millions of shares and led to increased selling pressure, Bloomberg reported on Tuesday.</li>
<li>Shares of NIP Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIPG#NASDAQ">NIPG</a>) were down 35% to $10.78. NIP Group announced the closing of its initial public offering and partial exercise of underwriters' option to purchase additional ADSs.</li>
<li>CNS Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNSP#NASDAQ">CNSP</a>) was down, falling 31% to $0.7169 after the company announced it entered into an exclusive license agreement with Cortice Biosciences.</li>
</ul>
Also Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/07/40036664/jim-cramer-says-no-to-this-health-care-stock-recommends-holding-on-to-constellation-ener">Jim Cramer Says No To This Health Care Stock, Recommends Holding On To Constellation Energy: &#8216;It&#8217;s Up A Huge Amount&#8217;</a>
Commodities In commodity news, oil traded down 1.3% to $74.81 while gold traded up 0.5% at $2,438.40.
Silver traded up 1% to $28.145 on Tuesday, while copper fell 0.9% to $4.0485.
Euro zone
European shares were mostly higher today. The eurozone's STOXX 600 rose 0.7%, Germany's DAX gained 0.7% and France's CAC 40 climbed 0.7%. Spain's IBEX 35 Index rose 0.9%, while London's FTSE 100 fell 0.1%.
The Euro Area GDP grew by 0.3% on quarter during the second quarter, the same as in the prior period but above expectations of 0.2%. The economic sentiment indicator in the Eurozone slipped to 95.8 in July from 95.9 in the prior month, while services sentiment indicator fell to 4.8 in July from a revised 6.2 in the prior month.
The German economy shrank 0.1% on quarter during the second quarter, compared to a 0.2% increase in the prior quarter, while Spanish economy expanded by 0.8% quarter-over-quarter in the second quarter. The French economy grew by 0.3% quarter-over-quarter during the second quarter.
Asia Pacific Markets
Asian markets closed mixed on Tuesday, with Japan's Nikkei 225 gaining 0.15%, Hong Kong's Hang Seng Index dipping 1.37%, China's Shanghai Composite Index falling 0.43% and India's S&amp;P BSE Sensex rising 0.12%.
Japanese unemployment rate came in at 2.5% for June, versus market projections of 2.6%.
Economics
<ul>
<li>The number of job openings came in at 8.184 million in June compared to a revised 8.23 million in May.</li>
<li>The S&amp;P CoreLogic Case-Shiller 20-city home price index rose 6.8% year-over-year in May versus a revised 7.3% gain in April.</li>
<li>The FHFA house price index came in unchanged for May.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/24/07/40036623/wall-streets-most-accurate-analysts-weigh-in-on-3-industrials-stocks-with-over-4-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Weigh In On 3 Industrials Stocks With Over 4% Dividend Yields</a></li>
</ul>

Eurozone

Commodities

ATPC

CNSP

IMNN

NIPG

PCSA

Dow Jumps 200 Points; Pfizer Earnings Top Views

Ecolab shares are trading lower after the company reported worse-than-expected Q2 sales results.

NIP Group Shares Resumed Trade

Guidance

Sysco Exec Says Corporate Expenses Were Down 10% YoY In The Quarter

Trading Halt: Halt status updated at 10:10:00 AM ET: Quotation Resumption: News and Resumption Times

Crane shares are trading higher after the company reported better-than-expected Q2 financial results. Additionally, the company raised the midpoint of its FY24 EPS guidance.

RGEN

Repligen shares are trading higher. The company reported Q2 financial results.

Cantor Fitzgerald analyst Louise Chen reiterates Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) with a Overweight and maintains $215 price target.

Reiteration

Cantor Fitzgerald Reiterates Overweight on Johnson & Johnson, Maintains $215 Price Target

VUZI

Vuzix's Moviynt Subsidiary Receives SAP Certification For Mobilium Gateway 3.0 Solution With S/4HANA Cloud Private Edition; Aims To Bridge Mobile Devices And ERP Systems To Enhance Workflow Efficiency

Sysco Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYY#NYSE">SYY</a>) reported fourth-quarter FY24 sales growth of 4.2% to $20.556 billion,<a target="_blank" href="https://www.benzinga.com/pressreleases/24/07/g40034864/sysco-reports-fourth-quarter-and-full-year-2024-results" rel="noreferrer noopener"> missing the analyst consensus estimate of $20.573 billion.</a>
U.S. Foodservice operations sales rose 4.9% Y/Y, and International Foodservice sales grew 3.8%.
Gross profit increased 4.2% Y/Y to $3.8 billion, and the gross margin compressed 1 basis point to 18.7%.
The operating margin contracted 14 basis points to 4.8%, and operating income for the quarter rose 1.2% to $977 million. Non-GAAP operating margin expanded 11 basis points to 5.3%.
Adjusted EBITDA increased 5.4% Y/Y to $1.3 billion in the quarter. Adjusted EPS of $1.39 <a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">beat the analyst consensus of $1.38.</a>
Sysco held $696 million in cash and equivalents as of June 29. Operating cash flow for FY24 totaled $3 billion, with a free cash flow of $2.2 billion.
The company returned approximately $2.2 billion to shareholders via $1.2 billion of share repurchases and $1.0 billion of dividends.
&#8220;Fiscal 2025 kicks off the first year of our three-year financial growth algorithm. Our plans for consistent top- and bottom-line growth are built on our expectations for sustainable growth, operational excellence, and a balanced capital return profile. This long-term view reflects an expected compounded annual growth rate of&nbsp;4%-6%&nbsp;for net sales,&nbsp;6%-8%&nbsp;for adjusted EPS, and&nbsp;9-11%&nbsp;total shareholder returns,&#8221; said Kenny Cheung, Sysco&#8217;s Chief Financial Officer.
Price Action: SYY shares are trading higher by 0.79% at $73.84 at the last check Tuesday.
Photo via Wikimedia Commons

Equities

Food Products Distributor Sysco Misses On Revenue But Delivers on Q4 Earnings – What's in Store for FY25?

The Only Monthly Membership With a Positive ROI!

-

-

-

-

-

-

-

The Only Monthly Membership With a Positive ROI!

-

-

-

-

-

-

-

Comments

Piraeus Finl Hldgs

News

Latest news for Piraeus Finl Hldgs (OTC:BPIRF) Stock

Tuesday, March 24, 2020